文献速递肿瘤 PET/CT核素与放射性配体治疗

18F-FDG与18F-氟胆碱PET作为索拉非尼治疗晚期肝细胞癌的预后生物标志物:一项前瞻性多中心研究

18F-FDG and 18F-Fluorocholine PET as Prognostic Biomarkers in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Prospective Multicenter Study.
PubMed 文献 · J Nucl Med · 2026-04-30

该前瞻性多中心单臂试验纳入61例晚期肝细胞癌患者,最终分析36例,在索拉非尼治疗前及治疗1个月后行18F-FDG和18F-FCH PET/CT,随访1年。基线18F-FDG代谢肿瘤体积(MTV)≥18 cm3是多变量分析中死亡的独立预测因子,而18F-FCH参数无预后价值。

要点

  • 基线18F-FDG MTV≥18 cm3是索拉非尼治疗晚期HCC死亡的独立预测因子。
  • 基线18F-FDG TNR≥1.5、MTV≥18 cm3、TLG≥53均与死亡显著相关。
  • 18F-FCH PET/CT参数(基线和随访)未显示预后意义。

核心结论

  • 基线18F-FDG PET/CT确定的代谢肿瘤负荷是接受索拉非尼治疗的晚期肝细胞癌患者的强预后生物标志物。
  • 18F-FCH PET/CT未提供额外的预后信息。

研究设计与样本

  • 前瞻性开放标签单臂多中心PREMATHEP试验(NCT02847468;6个招募中心),纳入适合索拉非尼治疗的晚期肝细胞癌患者。
  • 患者于治疗开始前和治疗1个月后接受18F-FDG和18F-FCH PET/CT,提取SUVmax、TNR及体积参数(MTV、TLG、总胆碱激酶活性),随访1年。

主要发现

  • 单变量分析中,血清白蛋白低于36 g/L及反映基线高18F-FDG肿瘤负荷的参数与死亡显著相关:TNR≥1.5(HR 7.6;95%CI 2.2-26.5;P=0.001)、MTV≥18 cm3(HR 6.3;95%CI 2.1-19.3;P<0.001)、TLG≥53(HR 12.6;95%CI 2.9-55.2;P=0.002)。
  • 18F-FCH参数(基线和随访)及临床数据均无预后意义。
  • 多变量分析中,基线18F-FDG PET/CT的MTV≥18 cm3仍是死亡的独立预测因子(HR 6.6;95%CI 1.7-25.2;P<0.001)。

关键数值与推荐

  • 基线18F-FDG PET/CT MTV≥18 cm3为独立预后阈值(多变量HR 6.6;95%CI 1.7-25.2;P<0.001)。
  • 基线18F-FDG TNR≥1.5(HR 7.6;95%CI 2.2-26.5;P=0.001)和TLG≥53(HR 12.6;95%CI 2.9-55.2;P=0.002)在单变量分析中与死亡显著相关。

临床怎么用

  • 对拟接受索拉非尼治疗的晚期肝细胞癌患者,可考虑基线18F-FDG PET/CT测量MTV以辅助预后分层。
  • 18F-FCH PET/CT在此场景下不推荐用于预后评估。

局限性

  • 最终分析仅36例(均为男性),样本量小且性别单一。
  • 18F-FCH参数无预后意义的结果可能受样本量限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this study was to evaluate the clinical significance of studies with dual radiotracers, 18F-FDG and 18F-fluorocholine (18F-FCH), performed before and after 1 mo of sorafenib therapy, in patients with advanced hepatocellular carcinoma (HCC) for the prediction of 1-y survival. Methods: Patients with advanced HCC eligible for sorafenib therapy were recruited in the prospective open-label single-arm multicenter PREMETHEP trial (NCT02847468; 6 recruiting centers). Patients had to undergo 18F-FDG and 18F-FCH PET/CT before treatment initiation and 1 mo after to evaluate baseline and residual tumor metabolism. The following parameters were extracted from each scan: the SUVmax and tumor-to-normal-liver ratio (TNR) (SUVmax of the tumor divided by SUVmax of normal liver) for the more significant lesion, and the volumetric parameters of the intrahepatic tumor burden: metabolic tumor volume (MTV), total lesion glycolysis (TLG) for 18F-FDG, and total lesion choline kinase activity for 18F-FCH. The tumor metabolic response (change in SUVmax, TNR, MTV, TLG, and total lesion choline kinase activity) was also calculated. Patients were followed during 1 y after treatment initiation. Cox analysis was performed to determine predictors of death. Optimal thresholds for quantitative parameters were determined using logistic regressions with the Youden index method. Results: Among 61 patients included, 36 were considered for final analysis (all male; median age, 70 y). Twenty-one patients died during follow-up. On univariate analysis, a serum albumin level of less than 36 g/L and parameters reflecting high 18F-FDG tumor burden at baseline were significantly associated with death (TNR ≥ 1.5 [hazard ratio (HR), 7.6; 95% CI, 2.2-26.5; P = 0.001], MTV ≥ 18 cm3 [HR, 6.3; 95% CI, 2.1-19.3; P < 0.001], and TLG ≥ 53 [HR, 12.6; 95% CI, 2.9-55.2; P = 0.002]). In contrast, neither of the 18F-FCH parameters (baseline and follow-up) and clinical data had prognostic significance. On multivariate analysis, an MTV of at least 18 cm3 on baseline 18F-FDG PET/CT remained an independent predictor of death (HR, 6.6; 95% CI, 1.7-25.2; P < 0.001). Conclusion: Baseline metabolic tumor burden determined with 18F-FDG PET/CT is a strong prognostic biomarker in patients with advanced HCC receiving sorafenib therapy. 18F-FCH PET/CT does not provide additional prognostic information.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Cochet A, Besson V, Bertaut A, et al. 18F-FDG and 18F-Fluorocholine PET as Prognostic Biomarkers in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Prospective Multicenter Study. J Nucl Med. 2026. PMID: 42061943. doi:10.2967/jnumed.125.271382

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。